Gufic BioSciences Ltd
₹283.05
(0.37%)
Tue, 10 Mar 2026, 08:15 pm
Health Technology
Pharmaceuticals: Major
24.5KGufic BioSciences Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 36.26 | 105.22 | 92.18 | 30.45 | 41.12 | 30.42 | 26.55 | 14.81 | 9.35 | 23.93 | 44.11 | 56.71 | 51.13 | 26.98 | 20.15 | 25.05 | 25.18 | 22.70 | 32.39 | 48.44 |
| Price to book ratio | 6.12 | 4.62 | 4.82 | 1.56 | 2.92 | 2.42 | 2.10 | 2.21 | 1.52 | 3.70 | 9.58 | 13.80 | 15.56 | 7.86 | 3.53 | 6.39 | 8.97 | 5.20 | 5.33 | 5.61 |
| Price to sales ratio | 1.62 | 1.37 | 1.47 | 0.50 | 0.83 | 0.64 | 0.51 | 0.50 | 0.33 | 0.67 | 1.61 | 2.09 | 2.76 | 1.69 | 1.21 | 2.27 | 3.10 | 2.62 | 3.46 | 4.12 |
| Price to cash flow ratio | 16.77 | 15.19 | 0 | 9.86 | 31.97 | 0 | 16.11 | 32.42 | 5.63 | 14.69 | 0 | 0 | 0 | 0 | 13.05 | 14.36 | 23.93 | 0 | 0 | 32.88 |
| Enterprise value | 1.17B | 914.83M | 934.37M | 405.64M | 673.29M | 632.98M | 605.3M | 828.23M | 657.01M | 1.27B | 3.61B | 5.64B | 9.15B | 6.82B | 5.67B | 11.56B | 24.51B | 20.97B | 31.09B | 36.81B |
| Enterprise value to EBITDA ratio | 16.85 | 19.42 | 25.69 | 7.59 | 12.96 | 10.13 | 8.69 | 7.53 | 5.50 | 8.79 | 17.68 | 24.42 | 23.40 | 14.71 | 10.51 | 13.64 | 16.72 | 14.99 | 20.73 | 26.24 |
| Debt to equity ratio | 1.47 | 1.18 | 1.01 | 0.91 | 1.01 | 1.06 | 1.05 | 1.56 | 1.28 | 1.22 | 1.26 | 1.52 | 1.47 | 1.30 | 0.98 | 0.35 | 0.24 | 0.96 | 0.63 | 0.56 |
| Return on equity % | 0 | 4.37 | 5.46 | 5.08 | 7.21 | 8.17 | 8.05 | 15.94 | 17.64 | 15.67 | 24.09 | 25.40 | 36.08 | 34.09 | 22.17 | 32.85 | 43.31 | 25.84 | 19.57 | 12.29 |
Gufic BioSciences Ltd Ratios
The Gufic BioSciences Ltd Ratios page provides a complete fundamental analysis of Gufic BioSciences Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Gufic BioSciences Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Gufic BioSciences Ltd (NSE: GUFICBIO, BSE: 509079) is currently trading at ₹283.05, with a market capitalization of ₹28.24B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Gufic BioSciences Ltd remains a key stock for fundamental analysis using Gufic BioSciences Ltd Ratios.
Gufic BioSciences Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Gufic BioSciences Ltd P/E ratio currently stands at 48.44, making it one of the most tracked metrics in Gufic BioSciences Ltd Ratios.
Historically, the Gufic BioSciences Ltd P/E ratio has shown strong fluctuations:
- 2024: 48.44
- 2023: 32.39
- 2022: 22.70
- 2021: 25.18
- 2020: 25.05
The rising Gufic BioSciences Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Gufic BioSciences Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 5.61.
Historical P/B trend:
- 2024: 5.61
- 2023: 5.33
- 2022: 5.20
- 2021: 8.97
Gufic BioSciences Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Gufic BioSciences Ltd P/S ratio currently stands at 4.12, an important part of Gufic BioSciences Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 4.12
- 2023: 3.46
- 2022: 2.62
- 2021: 3.10
The rising Gufic BioSciences Ltd P/S ratio indicates improved revenue valuation by investors.
Gufic BioSciences Ltd Price to Cash Flow Ratio (P/CF)
The Gufic BioSciences Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 32.88.
Historical Gufic BioSciences Ltd Price to Cash Flow Ratio:
- 2024: 32.88
- 2023: 0
- 2022: 0
- 2021: 23.93
- 2020: 14.36
The rising Gufic BioSciences Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.
Gufic BioSciences Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Gufic BioSciences Ltd EV currently stands at ₹36.81B, representing the total company valuation including debt.
Historical EV trend:
- 2024: 36.81B
- 2023: 31.09B
- 2022: 20.97B
- 2021: 24.51B
Gufic BioSciences Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Gufic BioSciences Ltd EV/EBITDA ratio is currently 26.24, a key metric in Gufic BioSciences Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 26.24
- 2023: 20.73
- 2022: 14.99
- 2021: 16.72
Higher Gufic BioSciences Ltd EV/EBITDA suggests premium valuation.
Gufic BioSciences Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Gufic BioSciences Ltd D/E ratio is currently 0.56, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.56
- 2023: 0.63
- 2022: 0.96
- 2021: 0.24
Gufic BioSciences Ltd maintains moderate leverage with manageable risk.
Return on Equity (ROE %)
The Gufic BioSciences Ltd ROE currently stands at 12.29%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 12.29
- 2023: 19.57
- 2022: 25.84
- 2021: 43.31
Gufic BioSciences Ltd maintains stable profitability levels.
Gufic BioSciences Ltd Ratios Analysis Summary
The Gufic BioSciences Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Gufic BioSciences Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Gufic BioSciences Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800